Stock Evaluator: Fractyl Health, Inc. (GUTS)

Fractyl Health, Inc. GUTS

$0.70 0.01 1.35%
September 4, 2026 4:00:00 PM EST November 10, 2021 Volume: 440,223
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics GUTS Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $110.9 $423.0 22%
Shares Out (Mil) 158.6 41.5 72%
Institutional Ownership 97.4% 83.6% 74%
Float (Mil) 145.9 35.5 68%
Beta 2.32 0.88 95%
Avg Daily Volume (000s) 1,959 346 83%
Price Change
(52-week)
(22.6%) 65.4% 28%
Growth GUTS Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 11.8% na
Net Income (5yr) (35.8%) (5.8%) 11%
EPS (5yr) 39.1% 10.4% 88
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (56.8%) (15.5%) 5%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 4 6
Current EPS ($0.123) ($0.330) ($0.438)
Month Ago EPS ($0.138) ($0.390) ($0.498)
# Rev Up 2 0 2
# Rev Down 1 1 0
Three Months Ago EPS ($0.144) ($0.420) ($0.544)
Year/Year Chg (23.6%) (82.2%) (83.5%)
Financials GUTS Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $119 na
Net Income (TTM) (Mil) ($106) ($9) 11%
EPS (TTM) ($0.809) ($0.400) 23%
Operating Cash Flow (TTM) (Mil) ($82) ($3) 7%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $56 $23 40%
Enterprise Value (Q1) (Mil) $128 $376 23%
Valuation GUTS Industry
Median
Percentile
(All Stocks)
P/B na 2.85 na
P/E na 27.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.6 na
Ratios GUTS Industry
Median
Percentile
(All Stocks)
Gross Margin na 58.5% na
Net Margin na (6.9%) na
ROA (146.8%) (13.3%) 3%
ROE na (13.3%) na
Liabilities to Assets 102.0% 46.0% 94%
F-Score 2 4 7%

Fractyl Health, Inc. did not pass any screens on 9/4/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors